Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Study to investigate effectiveness of novel combination treatment for eradicating HIV

A Case Western Reserve University School of Medicine researcher has received a $2.5 million grant from Gilead Sciences, a California-based biopharmaceutical company, to see if two so-far separately-used AIDS treatments are even more effective when used as a pair.

1 Feb 2017

New immunotherapy active against mucosal melanoma and improves survival for bladder cancer patients

Clinical trials of a new immunotherapy, pembrolizumab, have shown that it prolongs life significantly for patients with bladder cancer and is active against a rare sub-type of melanoma, called mucosal melanoma.

30 Jan 2017

New biomarker helps better predict survival after surgical removal of colorectal metastases

Liver metastases are formed from cancer cells that have originated in other organs and migrated to the liver via the bloodstream. Colorectal cancer (cancer of the colon/rectum) can be successfully treated by surgical resection of the metastases in combination with chemotherapy.

23 Jan 2017

Biosimilars create chances to improve sustainability and affordability of cancer treatment

Biosimilars create opportunities for sustainable cancer care, says the European Society for Medical Oncology (ESMO) in a position paper published in ESMO Open.

18 Jan 2017

UCLA-led research finds promising results for more personalized head and neck cancer treatment

Researchers have found that people with advanced head and neck squamous cell carcinoma and the KRAS-variant inherited genetic mutation have significantly improved survival when given a short course of the drug cetuximab in combination with standard chemotherapy and radiation.

23 Dec 2016

TSRI scientists identify microbial natural products as abundant sources of potent anticancer drugs

Scientists from the Florida campus of The Scripps Research Institute have developed an efficient process to rapidly discover new “enediyne natural products” from soil microbes that could be further developed into extremely potent anticancer drugs.

22 Dec 2016

Leading journal publishes article about ciliate lipases as therapeutic candidates for oral treatment of EPI

Cilian AG, a biopharmaceutical company focused on the development of subunit vaccines, enzymes and monoclonal antibodies, announces that the European Journal of Gastroenterology & Hepatology, the international, peer-reviewed, online publication journal, has published an article entitled: Novel ciliate lipases for enzyme replacement during exocrine pancreatic insufficiency.

20 Dec 2016

New review highlights need to reassess use of biologics for treating rheumatoid arthritis patients

The use of biologics, which are generally made from human and/or animal materials, has significantly changed the management of rheumatoid arthritis over the last decade, becoming the cornerstone treatment for many patients.

19 Dec 2016

Researchers develop promising therapeutic antibodies against tumor-promoting MMPs

Researchers at the University of California, Riverside have camels and llamas to thank for their development of a new cancer treatment that is highly selective in blocking the action of faulty matrix metalloproteinases (MMPs).

16 Dec 2016

DuPont research project aims to enable global access for protein-based biologic medications

DuPont Industrial Biosciences today announced receipt of a grant from the Bill & Melinda Gates Foundation to support a new area of research. The research project, which commences immediately, aims to create new production systems to enable affordable, protein-based biologic medications, such as antibodies.

16 Dec 2016

Treatment with biosimilar drug improves progression-free survival in breast cancer patients

Among women with metastatic breast cancer, treatment with a drug that is biosimilar to the breast cancer drug trastuzumab resulted in an equivalent overall response rate at 24 weeks compared with trastuzumab, according to a study published online by JAMA.

1 Dec 2016

Combination treatment may be valuable therapeutic option for HER2-negative metastatic breast cancer

Finding the ideal combination of targeted, hormonal and chemotherapeutic agents to treat HER2-negative metastatic breast cancer has been challenging researchers for decades.

1 Dec 2016

Melanoma drug offers considerable added benefit for patients with advanced NSCLC

Pembrolizumab was initially introduced for the treatment of melanoma. Since July 2016, the monoclonal antibody has also been available for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults whose tumours express the T-cell receptor ligand PD-L1 and who have received a prior chemotherapy regimen.

22 Nov 2016

Results of high-impact clinical trials could improve kidney-related medical care

The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented at ASN Kidney Week 2016, November 15-20 at McCormick Place in Chicago, IL.

21 Nov 2016

Allergan, Amgen submit BLA for ABP 215 oncology biosimilar medicine to FDA

Amgen and Allergan plc. today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 215, a biosimilar candidate to Avastin (bevacizumab).

16 Nov 2016

Photoimmunotherapy may be promising treatment option to combat cancer

When Kerstin Stenson, MD, describes the innovative technique she is helping develop to fight cancer, it seems like she's describing a Tom Clancy military espionage novel.

15 Nov 2016

Compugen program shows potential for development of new immunotherapy treatments for solid tumors

Compugen Ltd., a leading predictive drug discovery company, today presented new data for its preclinical CGEN-15029 program demonstrating the potential for the development of new cancer immunotherapy treatments for solid tumors, including the potential for drug combination with current immune checkpoint blockers.

11 Nov 2016

Broadly neutralizing antibody delays return of viral rebound in HIV-1 infected individuals

The administration of VRC01, a potent and broadly neutralizing HIV-specific antibody, is safe, is well-tolerated, generated high plasma concentrations and modestly delayed the return of HIV viral rebound in HIV-1 infected individuals after they stopped receiving antiretroviral therapy, according to a study published in the New England Journal of Medicine by researchers at the University of Alabama at Birmingham, the National Institutes of Health and the University of Pennsylvania Penn Center for AIDS Research.

10 Nov 2016

New biologic medication shows promise in treating multi-drug resistant HIV patients

A new biologic medication - the first for HIV - is showing promise in treating patients with multidrug resistance, according to phase 3 research being presented at IDWeek 2016.

31 Oct 2016

Anti-inflammatory drugs may improve severity of depressive symptoms, study finds

Anti-inflammatory drugs similar to those used to treat conditions such as rheumatoid arthritis and psoriasis could in future be used to treat some cases of depression, concludes a review led by the University of Cambridge, which further implicates our immune system in mental health disorders.

18 Oct 2016

Monoclonal Antibody News and Research

Further Reading

Study to investigate effectiveness of novel combination treatment for eradicating HIV

New immunotherapy active against mucosal melanoma and improves survival for bladder cancer patients

New biomarker helps better predict survival after surgical removal of colorectal metastases

Biosimilars create chances to improve sustainability and affordability of cancer treatment

UCLA-led research finds promising results for more personalized head and neck cancer treatment

TSRI scientists identify microbial natural products as abundant sources of potent anticancer drugs

Leading journal publishes article about ciliate lipases as therapeutic candidates for oral treatment of EPI

New review highlights need to reassess use of biologics for treating rheumatoid arthritis patients

Researchers develop promising therapeutic antibodies against tumor-promoting MMPs

DuPont research project aims to enable global access for protein-based biologic medications

Treatment with biosimilar drug improves progression-free survival in breast cancer patients

Combination treatment may be valuable therapeutic option for HER2-negative metastatic breast cancer

Melanoma drug offers considerable added benefit for patients with advanced NSCLC

Results of high-impact clinical trials could improve kidney-related medical care

Allergan, Amgen submit BLA for ABP 215 oncology biosimilar medicine to FDA

Photoimmunotherapy may be promising treatment option to combat cancer

Compugen program shows potential for development of new immunotherapy treatments for solid tumors

Broadly neutralizing antibody delays return of viral rebound in HIV-1 infected individuals

New biologic medication shows promise in treating multi-drug resistant HIV patients

Anti-inflammatory drugs may improve severity of depressive symptoms, study finds

Immunology eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®